Mild HBOT delivers therapy at 1.3 to 1.5 ATA, usually in a soft chamber with air or masked concentrator oxygen. Clinical HBOT delivers 2.0 to 3.0 ATA with 100 percent oxygen in a hard chamber. The core difference is dose: arterial oxygen reaches roughly 230 mmHg at 1.3 ATA versus about 1,824 mmHg at 2.4 ATA, an eightfold gap that decides which conditions each protocol can actually treat.
This is a comparison of the therapy, not the tackle. For the device teardown, see our guide to hard-shell vs soft-shell chambers and our breakdown of what a mild hyperbaric chamber delivers. Here the question is what each pressure protocol does inside the body, what the studies support, and which one fits a given goal.
What Is the Difference Between Mild and Clinical HBOT?
The line is drawn by pressure. Mild hyperbaric oxygen therapy, often shortened to mHBOT, runs at 1.3 to 1.5 ATA. Most portable soft chambers cap at 1.3 ATA, so mHBOT in practice usually means 1.3 ATA with room air or a concentrator delivering 90 to 95 percent oxygen by mask. Clinical HBOT runs at 2.0 to 3.0 ATA with 100 percent medical-grade oxygen, either filling a monoplace chamber or delivered by mask inside a pressurized multiplace chamber.
That single number drives everything downstream: the dissolved oxygen dose, the regulatory status, the evidence base, and the cost. The hardware differences follow from the physics, which is why the two categories rarely overlap. For the underlying mechanics, our explainer on what a hyperbaric chamber is covers how pressure and oxygen concentration combine, and our look at the 1.5 ATA hyperbaric chamber explains why that specific pressure sits on the boundary between the two.
How Much More Oxygen Does Clinical Pressure Deliver?
Hyperbaric benefit comes from dissolving extra oxygen into blood plasma, over and above what hemoglobin carries. The amount dissolved rises with both pressure and the oxygen fraction breathed, so small changes in either move the dose substantially.
8x
Arterial oxygen reaches about 1,824 mmHg at 2.4 ATA on 100% oxygen versus roughly 230 mmHg at 1.3 ATA on air, an eightfold difference in delivered dose.
Burman, South African Medical Journal, 2019
At 1.3 ATA breathing air, the arterial oxygen partial pressure lands near 230 mmHg. At 2.4 ATA breathing 100 percent oxygen, it reaches roughly 1,824 mmHg. Those figures, reported by Burman in the South African Medical Journal in 2019, describe an eightfold difference in delivered oxygen. Tissue oxygen tension, measured at the skin surface in wound patients, rises steeply with pressure in the same way, which is why higher pressure reaches tissue depths that low-pressure protocols cannot.
The practical takeaway: mild and clinical protocols are not two settings on one dial that produce more or less of the same effect. They cross physiological thresholds. Some biological responses only switch on above a certain oxygen tension, which is why the evidence does not scale smoothly from one to the other.
What Does the Evidence Support at Each Pressure?
Clinical HBOT has the deeper record. Every one of the 14 conditions approved by the Undersea and Hyperbaric Medical Society, including diabetic wounds, radiation tissue injury, gas gangrene, carbon monoxide poisoning, and decompression sickness, was validated in hard chambers at 2.0 ATA or higher, supported by hundreds of peer-reviewed studies. Our summary of FDA-cleared HBOT indications lists them in full.
Mild HBOT has a thinner record. Its supporting human studies are mostly small and uncontrolled, which is enough to justify further research but not enough to carry a treatment claim for a specific condition. The signals from wellness use (recovery, fatigue, general inflammation) are suggestive rather than established.
The most instructive case is mild traumatic brain injury. Harch’s 2022 systematic review in Frontiers in Neurology found four randomized controlled trials meeting Level 1 evidence criteria at 1.5 ATA with 100 percent oxygen, while 1.3 ATA with air produced one positive and one negative study, and 2.4 ATA produced negative results for that condition. The review concluded that pressure within a narrow range mattered more than raw oxygen concentration. In other words, more pressure is not automatically better, and the effective window is condition-specific rather than a simple ladder. That finding is the strongest case that a lower-pressure protocol can produce measured clinical change, though 1.5 ATA sits at the top edge of the mild range and above what most 1.3 ATA soft chambers deliver. For a fuller look at the trial data, see our review of the soft vs hard chamber clinical data.
Which Conditions Need Clinical Pressure, and Where Might Mild Help?
For the UHMS indications, clinical pressure is not optional. Oxygen becomes bacteriostatic, meaning it suppresses bacterial and fungal growth, only above 1.5 ATA. That is why wound healing, necrotizing infection, and gas gangrene are treated exclusively at 2.0 ATA and up.
1.5 ATA
The threshold above which oxygen turns bacteriostatic. A 1.3 ATA soft chamber cannot reach it under any oxygen configuration, so it is the wrong tool for wound and infection indications.
Undersea and Hyperbaric Medical Society
Mild HBOT is generally used off-label for wellness goals: recovery, fatigue, general inflammation, and cognitive support in people without a diagnosed condition that requires clinical dosing. The mTBI data at 1.5 ATA is the strongest case that a lower-pressure protocol can produce measured clinical change. For anything on the approved list, mild protocols should not be treated as a substitute.
How Much Does Each Cost per Session and per Protocol?
Mild sessions in wellness settings typically run $75 to $150. Physician-supervised clinical HBOT runs about $200 to $600 per session, reflecting medical-grade equipment, hyperbaric-certified staff, and oxygen handling. Our full hyperbaric chamber cost guide breaks down clinic pricing and home ownership.
Protocols compound those numbers. A standard course is often 20 to 40 sessions. At clinical rates, a 40-session course can reach $8,000 to $24,000, and it is usually covered by insurance only for approved indications. A 40-session mild course at a wellness clinic lands nearer $3,000 to $6,000 and is rarely reimbursed. Home ownership shifts the math again: entry-level FDA-cleared soft chambers start near $4,000, which can beat repeat clinic visits for long-term wellness use.
Which Is Safer, Mild or Clinical HBOT?
Lower pressure carries lower risk. A 2023 prospective cohort study (Monge et al.) of patients treated at 1.45 ATA reported a 7.1 percent adverse event rate per session with no cases of objective barotrauma, and all events recorded were minor. Soft chambers running air rather than a concentrated oxygen atmosphere also carry very low fire risk.
7.1%
Per-session adverse event rate at 1.45 ATA, all events minor and with no objective barotrauma reported, in a 2023 prospective cohort.
Monge et al., Int J Transl Med Res Public Health, 2023
Clinical HBOT is safe under proper supervision but carries a heavier risk profile: ear and sinus barotrauma from faster or higher compression, temporary vision changes, and rare oxygen toxicity, which is why 100 percent oxygen environments follow strict fire protocols. Both protocols share common minor effects like ear pressure. Our guide to hyperbaric chamber side effects covers what to expect and how to reduce risk.
How Do You Choose Between Mild and Clinical HBOT?
Start from the goal, not the machine. If you have a diagnosed condition on the UHMS list, clinical HBOT at 2.0 ATA or higher is the evidence-backed path, and it belongs in a supervised facility. If your aim is general wellness, recovery, or accessible home use without a specific medical target, a mild protocol offers a favorable safety profile and a lower cost of entry, with the honest caveat that its evidence base is small.
Two rules keep expectations calibrated. First, do not use a mild chamber as a stand-in for a clinical indication. Second, hold onto the pressure-window finding: for at least one condition, 1.5 ATA outperformed both 1.3 and 2.4 ATA, so higher is not reliably better. Match the protocol to the target and the evidence, then decide between a clinic and home use.
Mild vs Clinical HBOT at a Glance
Mild vs Clinical HBOT
| Factor | Mild HBOT | Clinical HBOT |
|---|---|---|
| Pressure (ATA) | 1.3 to 1.5 | 2.0 to 3.0 |
| Arterial oxygen | ~230 mmHg (1.3 ATA, air) | ~1,824 mmHg (2.4 ATA, 100% O2) |
| FDA status | Cleared for acute mountain sickness only | Used for 14 UHMS-approved indications |
| Typical setting | Home or wellness clinic | Hospital or specialist HBOT center |
| Cost per session | $75 to $150 | $200 to $600 |
| Evidence level | Limited; small studies, few RCTs | Extensive; hundreds of peer-reviewed studies |
Frequently Asked Questions
Is mild HBOT as effective as clinical HBOT?
Not for approved medical conditions. Every UHMS-approved indication was validated at 2.0 ATA or higher, and mild pressure cannot reach the bacteriostatic threshold above 1.5 ATA. Mild HBOT shows suggestive but limited signals for wellness goals, backed mostly by small studies without control groups rather than randomized trials. For a diagnosed indication, clinical HBOT is the evidence-backed option.
Why is 1.5 ATA sometimes better than higher pressure?
For mild traumatic brain injury, Harch’s 2022 review in Frontiers in Neurology found the strongest results at 1.5 ATA with 100 percent oxygen, while 2.4 ATA was negative. The response appears to depend on a narrow pressure window rather than maximum oxygen, so higher pressure is not automatically more effective for every condition.
Can I treat a wound with a mild home chamber?
No. Wound healing relies on oxygen becoming bacteriostatic above 1.5 ATA and on tissue oxygen levels that only clinical pressure reaches. A 1.3 ATA soft chamber cannot deliver either, so diabetic wounds and infections need supervised clinical HBOT at 2.0 ATA or higher, per UHMS guidance.
Does insurance cover either protocol?
Clinical HBOT is often covered when used for an approved indication like diabetic wounds or radiation injury, though coverage varies by plan and requires documentation. Mild HBOT used off-label for wellness is rarely reimbursed, so most people pay out of pocket or buy a home chamber.
Sources
- Burman F. “Low-pressure fabric hyperbaric chambers.” South African Medical Journal, 2019. doi.org/10.7196/SAMJ.2019.v109i4.13524
- Harch PG. “Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy in Mild Traumatic Brain Injury Persistent Postconcussion Syndrome.” Frontiers in Neurology, 2022. doi.org/10.3389/fneur.2022.815056
- Monge C, Otto-Yáñez M, Norambuena M, Martínez R, et al. “Safety of Hyperbaric Oxygenation Treatment and Evaluation of Associated Clinical Parameters: A Single-Institutional Prospective Cohort Study.” International Journal of Translational Medical Research and Public Health, 2023. doi.org/10.21106/ijtmrph.430
- Undersea and Hyperbaric Medical Society. “UHMS Approved Indications for Hyperbaric Oxygen Therapy” (13th Edition reference). uhms.org
- U.S. Food and Drug Administration. “Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices: Letter to Health Care Providers,” 2021. fda.gov
- Hyperbaric oxygen therapy cost reference. regenerated.health/hbot-cost
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
